Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial

Sponsor
Tang-Du Hospital
Study ID
NCT07699770
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Neuromyelitis Optica Spectrum Disorders (NMOSD)
  • Neuropathic Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Crisugabalin — DRUG
    Crisugabalin 20-40mg bid
  • Placebo+Crisugabalin — DRUG
    Placebo+Crisugabalin

Study Details

This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.

Key Dates

First listed
Jul 13, 2026
Start date
Jun 15, 2026
Status verified
Jul 2026
Primary completion
Oct 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
110 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Crisugabalin group
    Si meining
  • Placebo Comparator: Placebo group
    Si meining

Primary Outcome Measure

Numeric Rating Scale (NRS) Pain Score [ Time Frame: Change from baseline in the Numeric Rating Scale (NRS) pain score after 2 and 10 weeks of treatment ]

Central Contacts

Related Studies